PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.23%
EBIT growth above 1.5x AXSM's 23.84%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
45.56%
Operating income growth 1.25-1.5x AXSM's 35.57%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
30.89%
Net income growth above 1.5x AXSM's 19.26%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
30.77%
EPS growth above 1.5x AXSM's 20.49%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
30.77%
Diluted EPS growth above 1.5x AXSM's 20.49%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.49%
OCF growth above 1.5x AXSM's 25.25%. David Dodd would confirm a clear edge in underlying cash generation.
98.49%
FCF growth above 1.5x AXSM's 25.25%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
94.54%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
94.54%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
94.54%
3Y OCF/share CAGR above 1.5x AXSM's 23.58%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-8.80%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-8.80%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-8.80%
Negative 3Y CAGR while AXSM is 11.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-273.39%
Negative equity/share CAGR over 10 years while AXSM stands at 360.64%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-273.39%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-273.39%
Negative 3Y equity/share growth while AXSM is at 280.02%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.09%
Negative asset growth while AXSM invests at 7.23%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.63%
We have a declining book value while AXSM shows 35.76%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
0.22%
Debt shrinking faster vs. AXSM's 2.81%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
-43.90%
We cut SG&A while AXSM invests at 7.86%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.